Two medicines, side by side
Benzonatate vs dextromethorphan
Benzonatate and dextromethorphan are both labeled for cough and cold. Pharmacies paid $0.0656 per benzonatate 100 mg capsule and $0.122 per unit (Dextromethorphan 15 mg softgel) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, benzonatate is a non-narcotic antitussive and dextromethorphan a sigma-1 agonist.
Check it at the source: the benzonatate FDA label on DailyMed (effective August 3, 2026); the dextromethorphan FDA label on DailyMed (effective August 27, 2026).
Highlights of the benzonatate record
Benzonatate (Tessalon) · label of August 3, 2026
Used for
From the label: indicationsBenzonatate capsules, USP are indicated for the symptomatic relief of cough.
On the market
- Earliest approval on file
- February 10, 1958
- Generic labelers
- 45 labelers
- Pharmacy cost
- $0.0656 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 7
Highlights of the dextromethorphan record
Dextromethorphan (Delsym) · label of August 27, 2026
Used for
From the label: indicationstemporarily relieves • cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants • the impulse to cough to help you get to sleep
On the market
- Earliest approval on file
- n/a
- Generic labelers
- 28 labelers
- Pharmacy cost
- $0.122 per unit
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Benzonatate label of August 3, 2026, Dextromethorphan label of August 27, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do benzonatate and dextromethorphan differ on the record?
In FDA's classes, benzonatate is a non-narcotic antitussive and dextromethorphan a sigma-1 agonist.
Generics: benzonatate since 1993; dextromethorphan none approved (Drugs@FDA).
| Benzonatate | Dextromethorphan | |
|---|---|---|
| Labeled for | Cough and cold | Cough and cold |
| Pharmacologic class | Non-narcotic Antitussive | Sigma-1 Agonist, Uncompetitive N-methyl-D-aspartate Receptor Antagonist |
| How it works (label) | n/a | n/a |
| Half-life (label) | n/a | n/a |
| Earliest approval on file (Drugs@FDA) | February 10, 1958 | n/a |
| First generic approved | January 29, 1993 | none |
| Generic labelers (NDC) | 45 labelers | 28 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0656 per capsule (Benzonatate 100 mg capsule) | $0.122 per unit (Dextromethorphan 15 mg softgel) |
| 12-month price change | -8% | +13% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 7 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 16,446 | 8,389 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to benzonatate
- every medicine labeled for the same conditions